Deutsche Bank Stick to Their Buy Rating for Qiagen NV

0

Deutsche Bank (DE:DBKGn) analyst Falko Friedrichs maintained a Buy rating on Qiagen (NYSE:QGEN) NV on Wednesday, setting a price target of EUR60, which is approximately 44.08% above the present share price of $49.29.

Friedrichs expects Qiagen NV to post earnings per share (EPS) of $0.39 for the third quarter of 2020.

The current consensus among 15 TipRanks analysts is for a Moderate Buy rating of shares in Qiagen, with an average price target of $56.55.
The analysts price targets range from a high of $71.02 to a low of $46.16.

In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $443.25 million and a net profit of $139.89 million. The company’s market cap is $11.28 billion.

According to TipRanks.com, Deutsche Bank analyst Falko Friedrichs is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 4.5% and a 49.15% success rate.

QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.

Share.

About Author

Leave A Reply